SCHEMBL4429626

SCHEMBL4429626

O=c1n(C2=CCNCC2)c2ccccc2n1S(=O)(=O)c1c(Cl)nc2sccn12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 10/20 0.55
MET P08581 7/20 0.45
HTR2C P28335 3/20 0.43
HTR7 P34969 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2A6 P11509 1/20 0.43
HTR2B P41595 1/20 0.43
ADRA2A P08913 2/20 0.41
ADRB2 P07550 1/20 0.41
CHRM2 P08172 1/20 0.41
S1PR1 P21453 1/20 0.41
C5AR1 P21730 1/20 0.41
SLC6A2 P23975 1/20 0.41
FPR3 P25089 1/20 0.41
HTR1D P28221 1/20 0.41
HTR1B P28222 1/20 0.41
HTR2A P28223 1/20 0.41
GPR183 P32249 1/20 0.41
ADRA1A P35348 1/20 0.41
HRH1 P35367 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4419809 0.86 HTR6 (0.55) HTR6HTR2CHTR7CYP3A4CYP2A6
SCHEMBL4425159 0.84 HTR6 (0.57) HTR6HTR2CHTR2AKDM4E
SCHEMBL4419385 0.77 MET (0.51) HTR6METHTR2CHTR7CYP3A4
SCHEMBL4417941 0.74 HTR6 (0.60) HTR6HTR2CCYP3A4HTR2AKDM4E
SCHEMBL4432173 0.73 HTR6 (0.59) HTR6HTR2CHTR2AKDM4ECCKBR
SCHEMBL4420503 0.72 HTR6 (0.61) HTR6HTR2CHTR7CYP3A4HTR2B
SCHEMBL4420871 0.72 HTR6 (0.61) HTR6HTR2CHTR7CYP3A4HTR2A
SCHEMBL4417784 0.72 HTR6 (0.60) HTR6METHTR2CHTR7CYP3A4
SCHEMBL4419390 0.72 HTR6 (0.57) HTR6HTR2CHTR7CYP3A4HTR2A
SCHEMBL4429587 0.71 HTR6 (0.59) HTR6HTR2CCYP3A4HTR2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544701-B2 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-06-09 US claimed
US-20050020575-A1 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-01-27 US claimed
US-7544701-B2 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-06-09 US disclosed
US-20050020575-A1 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020575-A1 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR1B HTR6 1/4885MET 1197/4885HTR2C 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.